Nan Fung Group Holdings Ltd
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Nan Fung Group Holdings Ltd reported 45 stock positions worth $107.9 million. Its top holding was Illumina (ILMN) at 15.2% of the portfolio, followed by Harmony Biosciences (HRMY, 11.5%) and Alpine Immune Sciences (ALPN, 9.7%). Compared with Q4 2023, it opened 11 new positions, sold out of 5, added to 11 and reduced 3. The biggest buy was a new position in Standard Biotools (LAB) and the biggest sale an exit from Karuna Therapeutics (KRTX).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $107.9M (Q1 2024)
- SEC Filing
- 0001012975-24-000206 ↗ filed May 14, 2024
Holdings Value
Holdings 45 stocks · $107.9M
| ILMN Illumina Inc. | 15.17% | 119,196 | $16.4M | No change |
| HRMY Harmony Biosciences Holdings | 11.47% | 368,665 | $12.4M | No change |
| ALPN Alpine Immune Sciences Inc. | 9.69% | 263,940 | $10.5M | No change |
| OCS Oculis Holding AG | 4.87% | 436,378 | $5.3M | Reduce -15.9% |
| LAB Standard Biotools Inc. | 4.73% | 1,883,179 | $5.1M | New |
| EXAI Exscientia Ltd. | 4.56% | 859,892 | $4.9M | No change |
| XENE Xenon Pharmaceuticals Inc. | 4.26% | 106,680 | $4.6M | No change |
| GERN Geron Corp. | 4.05% | 1,324,550 | $4.4M | Add +45.0% |
| INCY Incyte Corp. | 3.91% | 74,022 | $4.2M | Add +131.2% |
| MRUS Merus NV | 3.73% | 89,516 | $4.0M | Reduce -34.7% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 3.34% | 23,022 | $3.6M | Add +91.5% |
| KALV Kalvista Pharmaceuticals Inc. | 2.41% | 219,277 | $2.6M | Reduce -27.9% |
| LBPH Longboard Pharmaceuticals Inc. | 2.37% | 118,255 | $2.6M | New |
| MIRM Mirum Pharmaceuticals Inc. | 2.24% | 96,100 | $2.4M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 1.97% | 49,120 | $2.1M | Add +22.6% |
| ASND Ascendis Pharma A/S | 1.91% | 13,600 | $2.1M | New |
| ACAD Acadia Pharmaceuticals Inc. | 1.76% | 102,984 | $1.9M | Add +243.5% |
| REPL Replimune Group Inc. | 1.55% | 204,939 | $1.7M | Add +10.9% |
| BOLT Bolt Biotherapeutics Inc. | 1.51% | 1,166,952 | $1.6M | No change |
| RANI Rani Therapeutics Holdings Class A | 1.42% | 493,584 | $1.5M | No change |
| EXEL Exelixis Inc. | 1.41% | 64,200 | $1.5M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 1.41% | 5,682 | $1.5M | Add +380.7% |
| AEROVATE THERAPEUTICS INC | 1.31% | 47,936 | $1.4M | No change |
| PACB Pacific Biosciences of Calif | 0.95% | 274,488 | $1.0M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 0.88% | 10,815 | $945K | Add +199.2% |
| NMRA Neumora Therapeutics Inc. | 0.81% | 63,315 | $871K | New |
| CABA Cabaletta Bio Inc. | 0.75% | 47,150 | $804K | No change |
| TRDA Entrada Therapeutics Inc. | 0.64% | 49,082 | $695K | No change |
| BMEA Biomea Fusion Inc. | 0.55% | 40,000 | $598K | No change |
| ATHIRA PHARMA INC | 0.46% | 180,000 | $493K | No change |
| TRML Tourmaline Bio Inc. | 0.45% | 20,987 | $481K | New |
| ALXO Alx Oncology Holdings Inc. | 0.43% | 41,950 | $468K | No change |
| IMCR Immunocore Holdings PLC-ADR | 0.41% | 6,750 | $439K | New |
| KYMR Kymera Therapeutics Inc. | 0.41% | 10,875 | $437K | New |
| SWTX Springworks Therapeutics Inc. | 0.34% | 7,450 | $367K | New |
| ROIV Roivant Sciences Ltd. | 0.32% | 32,470 | $342K | New |
| DBV TECHNOLOGIES S A | 0.26% | 370,950 | $278K | No change |
| RVMD Revolution Medicines Inc. | 0.22% | 7,300 | $235K | New |
| ABCL Abcellera Biologics Inc. | 0.21% | 50,971 | $231K | Add +307.1% |
| AFMDQ Affimed NV | 0.18% | 37,247 | $197K | No change |
| BCRX Biocryst Pharmaceuticals Inc. | 0.17% | 36,847 | $187K | Add +106.5% |
| KOD Kodiak Sciences Inc. | 0.16% | 31,922 | $168K | Add +62.7% |
| IMTX Immatics NV | 0.15% | 15,700 | $165K | New |
| FIBROGEN INC | 0.14% | 62,106 | $146K | No change |
| GALERA THERAPEUTICS INC | 0.08% | 613,223 | $86K | No change |
Portfolio Sells Q4 2023 → Q1 2024
| KRTX Karuna Therapeutics Inc. | Sold out | 0.00% | −44.49 |
| SLGC Somalogic Inc. | Sold out | 0.00% | −2.67 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −0.34 |
| EAR Eargo Inc. | Sold out | 0.00% | −0.24 |
| CERS Cerus Corp. | Sold out | 0.00% | −0.02 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -27.9% | 2.41% | +0.09 |
| OCS Oculis Holding AG | Reduce -15.9% | 4.87% | +1.24 |
| MRUS Merus NV | Reduce -34.7% | 3.73% | +1.39 |
Portfolio Buys Q4 2023 → Q1 2024
| LAB Standard Biotools Inc. | New | 4.73% | +4.73 |
| GERN Geron Corp. | Add +45.0% | 4.05% | +2.85 |
| INCY Incyte Corp. | Add +131.2% | 3.91% | +2.66 |
| LBPH Longboard Pharmaceuticals Inc. | New | 2.37% | +2.37 |
| ONC Beone Medicines Ltd.-ADR | Add +91.5% | 3.34% | +1.99 |
| ASND Ascendis Pharma A/S | New | 1.91% | +1.91 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +380.7% | 1.41% | +1.24 |
| ACAD Acadia Pharmaceuticals Inc. | Add +243.5% | 1.76% | +1.18 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +22.6% | 1.97% | +0.82 |
| NMRA Neumora Therapeutics Inc. | New | 0.81% | +0.81 |
| BMRN Biomarin Pharmaceutical Inc. | Add +199.2% | 0.88% | +0.66 |
| REPL Replimune Group Inc. | Add +10.9% | 1.55% | +0.58 |
| TRML Tourmaline Bio Inc. | New | 0.45% | +0.45 |
| IMCR Immunocore Holdings PLC-ADR | New | 0.41% | +0.41 |
| KYMR Kymera Therapeutics Inc. | New | 0.41% | +0.41 |
| SWTX Springworks Therapeutics Inc. | New | 0.34% | +0.34 |
| ROIV Roivant Sciences Ltd. | New | 0.32% | +0.32 |
| RVMD Revolution Medicines Inc. | New | 0.22% | +0.22 |
| ABCL Abcellera Biologics Inc. | Add +307.1% | 0.21% | +0.17 |
| IMTX Immatics NV | New | 0.15% | +0.15 |
| KOD Kodiak Sciences Inc. | Add +62.7% | 0.16% | +0.12 |
| BCRX Biocryst Pharmaceuticals Inc. | Add +106.5% | 0.17% | +0.11 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |